The European Commission has expanded marketing authorization for enzalutamide to include treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy and in whom chemotherapy is not yet clinically indicated. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, enzalutamide, Europe | Leave a comment »
Late last week the Committee for Medicinal Products for Human Use (CHMP) in Europe recommended expansion of the marketing authorization for enzalutamide within member states of the European Union. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: enzalutamide, Europe | Leave a comment »
So one of the presentations given at the recent EAU meeting in Stockholm was an update, by Dr. Jonas Hugosson, at a median 13 years of follow-up, from the European Randomized Study of Screening for Prostate Cancer (ERSPC) — and there is some good news, but maybe not enough to get carried away by … yet. READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: ERSPC, Europe, risk, screening, testing | 6 Comments »
According to a media release this morning from Medivation and Astellas Pharma, the companies have completed submission of data in support of the expansion of the European Marketing Authorization for enzalutamide — to include men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, Europe | Leave a comment »
According to a media release issued earlier today, Dendreon is planning to make sipuleucel-T (Provenge) available in Europe, beginning with Germany and the United Kingdom. However, the media release is short on any precision regarding the dates of such availability. … READ MORE …
Filed under: Management, Treatment | Tagged: access, Europe, sipuleucel-T | Leave a comment »
The European Association of Urology (EAU) has just updated its guideline document “EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, Europe, guideline, Management, risk, screening, Treatment | Leave a comment »
The European Medicines Agency’s Committee for Medicinal Products for Human Use today recommended that marketing authorization be approved for sipuleucel-T (Provenge) in the European Union. A final decision by the European Commission is likely later this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, Europe, Provenge, sipuleucel-T | Leave a comment »
Yesterday, the European Commission approved the use of enzalutamide (Xtandi) for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) in men who have progressive disease after at least one cycle of docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, enzalutamide, Europe, mCRPC | 2 Comments »
According to a summary statement of opinion issued yesterday by the Committee for Medicinal Products for Human Use (CMPH) of the European Mediciens Agency (EMEA), CMPH is recommending an expanded indication for the clinical use of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: abiraterone, Europe, indication, Zytiga | 4 Comments »
Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, approval, Europe | Leave a comment »
Last Friday the European Medicines Agency (EMEA) gave approval for the marketing of abiraterone acetate (Zytiga™) for the treatment of metastatic, castration-resistant prostate cancer in men who have already progressed after treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, approval, Europe, Zytiga | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 